BioTek Instruments Achieves Record Sales Growth, Community Awards in 2009
January 21, 2010
BioTek Instruments, Inc., a leader in microplate instrumentation technology, announced 13% sales growth for the fiscal year ending December 31, 2009, which significantly outpaced the overall laboratory instrumentation market, which contracted during the same period. An extremely strong December performance contributed to a record-breaking fourth quarter, and year, for the Company. Spurred on by growth in spite of a market and global economic slump, the company reinvested heavily in R&D, Marketing, Sales and Service activities including:
- Multi-Lingual Web Sites (English, Spanish, French, German, Chinese, Japanese)
- 8,000 square-foot expansion of a new Service Center and Applications Laboratory
- 4,000 square-foot addition in Manufacturing
In addition to sales growth milestones, the Vermont community recognized BioTek in 2009. Vermont Business Magazine named BioTek as Vermont’s Best Place to Work (Large Company), and the Lake Champlain Regional Chamber of Commerce awarded BioTek as 2009 Business of the Year. The Company was also a finalist for the Deane C. Davis Outstanding Business of the Year.
“None of this would be possible without the combined dedication of the entire BioTek team,” noted Briar Alpert, President & CEO of BioTek Instruments. “We continually invest in our employees, our greatest strength. In return our employees reward us with longevity that is virtually unknown in today’s society and a driving factor in our success.” Mr. Alpert cited an increase of almost 50% in the number of BioTek employees in the past five years, with 18% having worked at the company for more than 20 years.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For further information, contact:
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications